As filed with the U.S. Securities and Exchange Commission on January 28, 2026.
Registration No. 333-270717
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-6
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOR
DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS
ROCHE HOLDING LTD
(Exact name of issuer of deposited securities as specified in its charter)
N/A
(Translation of issuer's name into English)
Switzerland
(Jurisdiction of incorporation or organization of issuer)
JPMORGAN CHASE BANK, N.A.
(Exact name of depositary as specified in its charter)
270 Park Avenue, Floor 8
New York, New York 10017
Telephone: +1-800- 990-1135
(Address, including zip code, and telephone number, including area code, of depositary's principal executive offices)
Roche Holdings, Inc.
1 DNA Way
South San Francisco, California 94080
Telephone: +1-650-225-1000
(Address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
|
JPMorgan Chase Bank, N.A. New York, New York 10017 Telephone: +1-800-990-1135
|
Scott R. Saks, Esq. Norton Rose Fulbright US LLP 1301 Avenue of the Americas New York, New York 10019-6022 Telephone: +1-212-318-3151 |
It is proposed that this filing become effective under Rule 466
¨ immediately upon filing
¨ on (Date) at (Time)
If a separate registration statement has been filed to register the deposited shares, check the following box. ¨
CALCULATION OF REGISTRATION FEE
|
Title of Each Class of Securities to be Registered |
Amount to be Registered |
Proposed Maximum Aggregate Price Per Unit (1) |
Proposed Maximum Aggregate Offering Price (2) |
Amount of Registration Fee |
| American Depositary Shares, evidenced by American Depositary Receipts, each American Depositary Share representing one-eighth (1/8th) of one participation certificate (Partizipationsschein) with a nominal value of CHF 0.001 of Roche Holding Ltd | N/A | N/A | N/A | N/A |
| (1) | Each unit represents one American Depositary Share. | |
| (2) | Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of American Depositary Receipts evidencing American Depositary Shares. |
The Registrant hereby amends this Post-Effective Amendment No. 1 to the Registration Statement on Form F-6 on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Post-Effective Amendment No. 1 to the Registration Statement on Form F-6 shall thereafter become effective in accordance with Section 8(c) of the Securities Act of 1933 or until this Post-Effective Amendment No. 1 to the Registration Statement on Form F-6 shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said Section 8(c), may determine.
PART I
INFORMATION REQUIRED IN PROSPECTUS
The Prospectus consists of the proposed form of American Depositary Receipt ("ADR" or "American Depositary Receipt") included as Exhibit A to the form of Amendment No. 1 to the Fourth Amended and Restated Deposit Agreement filed as Exhibit (a)(2) to this Post-Effective Amendment No. 1 to the Registration Statement on Form F-6, which is incorporated herein by reference.
Item 1. DESCRIPTION OF SECURITIES TO BE REGISTERED
CROSS REFERENCE SHEET
| Item Number and Caption | |
Location in Form of American Depositary Receipt Filed Herewith as Prospectus |
||
| 1. | Name of the depositary and the address of its principal executive office | Introductory paragraph and bottom of face of American Depositary Receipt | ||
| 2. | Title of the American Depositary Receipts and identity of the deposited securities | Face of American Depositary Receipt, top center | ||
| Terms of Deposit: | ||||
| (a) | Amount of deposited securities represented by one unit of American Depositary Receipts | Face of American Depositary Receipt, upper right corner | ||
| (b) | Procedure for voting the deposited securities | Paragraphs (6), (11) and (12) | ||
| (c) | Procedure for collecting and distributing dividends | Paragraphs (4), (5), (7), (10), (11), (13) and (21) | ||
| (d) | Procedures for transmitting notices, reports and proxy soliciting material | Paragraphs (3), (8), (11) and (12) | ||
| (e) | Sale or exercise of rights | Paragraphs (4), (5), (7) and (10) | ||
| (f) | Deposit or sale of securities resulting from dividends, splits or plans of reorganization | Paragraphs (3), (4), (5), (7), (10), (11), (13) and (21) | ||
| (g) | Amendment, extension or termination of the deposit arrangements | Paragraphs (15), (16) and (17) | ||
| (h) | Rights that holders of American Depositary Receipts have to inspect the books of the depositary and the list of receipt holders | Paragraph (3) | ||
| Item Number and Caption |
|
Location in Form of American Depositary Receipt Filed Herewith as Prospectus |
||
| (i) | Restrictions on the right to transfer or withdraw the underlying securities | Paragraphs (1), (2), (4), (5) and (6) | ||
| (j) | Limitation on the depositary’s liability | Paragraphs (14), (17), (19) and (20) | ||
| 3. | Fees and charges that a holder of American Depositary Receipts may have to pay, either directly or indirectly | Paragraph (7) | ||
| 4. | Fees and other direct and indirect payments made by the depositary to the foreign issuer of the deposited securities | Paragraph (7) | ||
| Item 2. AVAILABLE INFORMATION | Paragraph (8) | |||
| Roche Holding Ltd (the “Company”) publishes information in English required to maintain the exemption from registration under the Securities Exchange Act of 1934, as amended, afforded by Rule 12g3-2(b) promulgated thereunder on its Internet Web site or through an electronic information delivery system generally available to the public in its primary trading market. As of the date hereof, the Company’s internet website is located at www.roche.com. | ||||
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 3. EXHIBITS
| (a)(1) | Form of Deposit Agreement. Form of Fourth Amended and Restated Deposit Agreement (as from time to time amended, the "Deposit Agreement"), among Roche Holding Ltd (the “Company”), JPMorgan Chase Bank, N.A., as depositary (the "Depositary"), and all Holders and Beneficial Owners from time to time of American Depositary Receipts (“ADRs”) issued thereunder. Previously filed. |
| (a)(2) | Form of Amendment No. 1 to the Deposit Agreement. Form of Amendment No. 1 to the Deposit Agreement among the Company, the Depositary, and all Holders and Beneficial Owners from time to time of ADRs issued thereunder, including the Form of ADR attached as Exhibit A thereto. Filed herewith as Exhibit (a)(2). |
| (b) | Any other agreement to which the Depositary is a party relating to the issuance of the American Depositary Shares registered hereby or the custody of the deposited securities represented thereby. Not Applicable. |
| (c) | Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. Not Applicable. |
| (d) | Opinion of Norton Rose Fulbright US LLP, counsel to the Depositary, as to the legality of the securities being registered. Previously filed. |
| (e) | Certification under Rule 466. Not Applicable. |
| (f) | Power of Attorney of certain officers and directors of the Company. Set forth on the signature pages hereto. |
Item 4. UNDERTAKINGS
| (a) | The Depositary hereby undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of the American Depositary Receipts, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer. |
| (b) | If the amounts of fees charged are not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an American Depositary Receipt thirty days before any change in the fee schedule. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, JPMorgan Chase Bank, N.A., acting solely in its capacity as depositary (the “Depositary”) on behalf of the legal entity created by the Fourth Amended and Restated Deposit Agreement (the “Deposit Agreement”) among Roche Holding Ltd, the Depositary and all Holders and Beneficial Owners from time to time of American Depositary Receipts (“ADRs”) issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in The City of New York, State of New York, on January 28, 2026.
| Legal entity created by the Deposit Agreement for the | ||||
| issuance of ADRs evidencing American Depositary | ||||
| Shares | ||||
| By: | JPMORGAN CHASE BANK, N.A., solely in its | |||
| capacity as Depositary | ||||
| By: | /s/ Gregory A. Levendis | |||
| Name: | Gregory A. Levendis | |||
| Title: | Executive Director | |||
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, Roche Holding Ltd certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in Basel, Switzerland, on January 28, 2026.
| ROCHE HOLDING LTD | |||
| By: | /s/ Florian Regli | ||
| Name: | Florian Regli | ||
| Title: | Authorized Signatory | ||
| By: | /s/ Peter Trybus | ||
| Name: | Peter Trybus | ||
| Title: | Authorized Signatory | ||
POWERS OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Peter Trybus, Dr. Alan Hippe, Britta Döttger and Florian Regli, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this Registration Statement and any and all related registration statements pursuant to Rule 462(b) of the Securities Act, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to the Registration Statement on Form F-6 has been signed by the following persons in the capacities indicated on January 28, 2026.
SIGNATURES
| Signature | Title | |
| /s/ Dr. Severin Schwan | ||
| Dr. Severin Schwan | Director, Chairman of the Board | |
| /s/ Thomas Michael Schinecker | ||
| Thomas Michael Schinecker | Chief Executive Officer | |
| (principal executive officer) | ||
| /s/ André Hoffmann | ||
| André Hoffmann | Director, Vice Chairman of the Board | |
| /s/ Dr. Jörg Duschmalé | ||
| Dr. Jörg Duschmalé | Director | |
| /s/ Dr. Patrick Frost | ||
| Dr. Patrick Frost | Director | |
| /s/ Anita Magdalena Hauser | ||
| Anita Magdalena Hauser | Director | |
| /s/ Prof. Dr. Akiko Iwasaki | ||
| Prof. Dr. Akiko Iwasaki | Director | |
| /s/ Richard Priestley Lifton | ||
| Richard Priestley Lifton | Director | |
| /s/ Dr. Jemilah Binti Mahmood | ||
| Dr. Jemilah Binti Mahmood | Director | |
| /s/ Dr. Mark Schneider | ||
| Dr. Mark Schneider | Director | |
| /s/ Dr. Claudia Suessmuth Dyckerhoff | ||
| Dr. Claudia Suessmuth Dyckerhoff | Director | |
| /s/ Dr. Alan Hippe | ||
| Dr. Alan Hippe | Chief Financial Officer | |
| (principal financial and accounting officer) | ||
| /s/ Roger Brown | ||
| Roger Brown | Authorized U.S. Representative |
INDEX TO EXHIBITS